JP2018535929A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535929A5
JP2018535929A5 JP2018515603A JP2018515603A JP2018535929A5 JP 2018535929 A5 JP2018535929 A5 JP 2018535929A5 JP 2018515603 A JP2018515603 A JP 2018515603A JP 2018515603 A JP2018515603 A JP 2018515603A JP 2018535929 A5 JP2018535929 A5 JP 2018535929A5
Authority
JP
Japan
Prior art keywords
subject
concentration
pharmaceutical formulation
item
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018515603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535929A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/053269 external-priority patent/WO2017053677A1/en
Publication of JP2018535929A publication Critical patent/JP2018535929A/ja
Publication of JP2018535929A5 publication Critical patent/JP2018535929A5/ja
Priority to JP2021181755A priority Critical patent/JP2022010141A/ja
Priority to JP2024120967A priority patent/JP2024147801A/ja
Withdrawn legal-status Critical Current

Links

JP2018515603A 2015-09-24 2016-09-23 アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤 Withdrawn JP2018535929A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021181755A JP2022010141A (ja) 2015-09-24 2021-11-08 アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤
JP2024120967A JP2024147801A (ja) 2015-09-24 2024-07-26 アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562232242P 2015-09-24 2015-09-24
US62/232,242 2015-09-24
US201662323182P 2016-04-15 2016-04-15
US62/323,182 2016-04-15
US201662365544P 2016-07-22 2016-07-22
US62/365,544 2016-07-22
PCT/US2016/053269 WO2017053677A1 (en) 2015-09-24 2016-09-23 Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021181755A Division JP2022010141A (ja) 2015-09-24 2021-11-08 アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤

Publications (2)

Publication Number Publication Date
JP2018535929A JP2018535929A (ja) 2018-12-06
JP2018535929A5 true JP2018535929A5 (enExample) 2019-10-31

Family

ID=57113749

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018515603A Withdrawn JP2018535929A (ja) 2015-09-24 2016-09-23 アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤
JP2021181755A Pending JP2022010141A (ja) 2015-09-24 2021-11-08 アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤
JP2024120967A Pending JP2024147801A (ja) 2015-09-24 2024-07-26 アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021181755A Pending JP2022010141A (ja) 2015-09-24 2021-11-08 アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤
JP2024120967A Pending JP2024147801A (ja) 2015-09-24 2024-07-26 アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤

Country Status (18)

Country Link
US (3) US10512675B2 (enExample)
EP (1) EP3352787A1 (enExample)
JP (3) JP2018535929A (enExample)
KR (1) KR102805910B1 (enExample)
CN (1) CN108778323A (enExample)
AU (2) AU2016326602A1 (enExample)
BR (1) BR112018006074A2 (enExample)
CA (1) CA2999297A1 (enExample)
CL (1) CL2018000740A1 (enExample)
IL (2) IL297353B2 (enExample)
MA (1) MA42934A (enExample)
MX (1) MX2018003702A (enExample)
PE (2) PE20241346A1 (enExample)
PH (1) PH12018500594A1 (enExample)
RU (2) RU2020126034A (enExample)
TW (3) TW202446416A (enExample)
WO (1) WO2017053677A1 (enExample)
ZA (1) ZA201801657B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3215191B1 (en) 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
JP2018535929A (ja) * 2015-09-24 2018-12-06 バイオマリン ファーマシューティカル インコーポレイテッド アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤
US10143760B2 (en) 2015-10-28 2018-12-04 Sangamo Therapeutics, Inc. Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
JP6994018B2 (ja) 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド 新規アデノ随伴ウイルスキャプシドタンパク質
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
US11452749B2 (en) 2017-07-10 2022-09-27 Uniqure Ip B.V. Means and methods for AAV gene therapy in humans
US20200237930A1 (en) * 2017-08-01 2020-07-30 Spark Therapeutics, Inc. Factor viii (fviii) gene therapy methods
CN111936621B (zh) * 2018-02-05 2025-05-13 奥登茨治疗公司 转录调控元件和它的用途
US20210093735A1 (en) * 2018-04-26 2021-04-01 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of hemophilia
KR20210008501A (ko) 2018-05-09 2021-01-22 바이오마린 파머수티컬 인크. 페닐케톤뇨증을 치료하는 방법
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
CN112424345A (zh) * 2018-05-14 2021-02-26 生物马林药物股份有限公司 Aav载体在青少年对象中的稳定表达
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
US12091675B2 (en) * 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
AU2019314513B2 (en) * 2018-08-03 2026-04-30 Sangamo Therapeutics, Inc. Improved clinical parameters by expression of factor viii
CN113226352B (zh) * 2018-08-24 2025-08-26 星火治疗有限公司 最优化启动子序列、无内含子的表达结构及使用方法
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
SG11202108357PA (en) 2019-02-15 2021-08-30 Crispr Therapeutics Ag Gene editing for hemophilia a with improved factor viii expression
KR20210151785A (ko) 2019-03-13 2021-12-14 제너레이션 바이오 컴퍼니 비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도
JP7853100B2 (ja) 2019-06-05 2026-04-28 オーチャード セラピューティクス(ヨーロッパ)リミテッド 真核細胞を修飾するための組成物及び方法
CN114375205A (zh) * 2019-06-20 2022-04-19 武田药品工业株式会社 用基于病毒的基因疗法进行治疗的方法
WO2021084276A2 (en) 2019-11-01 2021-05-06 Freeline Therapeutics Limited Factor viii construct
AU2020395323A1 (en) * 2019-12-06 2022-06-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor VIII function
CN114981299A (zh) * 2019-12-12 2022-08-30 武田药品工业株式会社 使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法
KR102167829B1 (ko) * 2020-02-10 2020-10-20 주식회사 이노테라피 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復pah基因功能的腺相關病毒組成物及其使用方法
US12540333B2 (en) * 2020-11-02 2026-02-03 Regeneron Pharmaceuticals, Inc. Characterization of impurities in adeno-associated virus (AAV) samples and formulation compositions to stabilize AAV
KR20230078805A (ko) 2020-11-02 2023-06-02 바이오마린 파머수티컬 인크. 아데노-연관 바이러스의 농축 공정
CN116350801A (zh) 2022-11-22 2023-06-30 四川至善唯新生物科技有限公司 一种重组腺相关病毒载体的药物组合物及其用途
WO2025045082A1 (zh) * 2023-09-01 2025-03-06 康霖生物科技(杭州)有限公司 一种缓冲系统及其相应液体制剂及其用途
WO2026019230A1 (ko) * 2024-07-15 2026-01-22 삼성바이오에피스 주식회사 스터퍼를 포함하는 재조합 aav 생산을 위한 벡터 시스템

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DK518384A (da) 1984-01-31 1985-07-01 Idaho Res Found Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
EP0933997A4 (en) 1996-09-06 2000-08-16 Chiron Corp METHODS AND COMPOSITIONS FOR LIVER-SPECIFIC ADMINISTRATION OF THERAPEUTIC MOLECULES USING RECOMBINANT AAV VECTORS
WO1999061595A2 (en) 1998-05-27 1999-12-02 Cell Genesys, Inc. Adeno-associated viral vector-mediated expression of factor viii activity
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
WO2003074714A1 (en) 2002-03-05 2003-09-12 Stichting Voor De Technische Wetenschappen Baculovirus expression system
ES2436741T3 (es) 2004-09-22 2014-01-07 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
CA2703948A1 (en) * 2007-11-01 2009-05-07 University Of Rochester Recombinant factor viii having increased stability
US7943379B2 (en) 2008-04-30 2011-05-17 Nationwide Children's Hospital, Inc. Production of rAAV in vero cells using particular adenovirus helpers
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
BR112014020325A2 (pt) 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
US20140003880A1 (en) * 2012-06-30 2014-01-02 General Electric Company Ceramic matrix composite and metal attachment configurations
DK2911687T3 (da) * 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
ES2813698T3 (es) 2013-09-12 2021-03-24 Biomarin Pharm Inc Vectores de AAV que comprenden un gen que codifica el factor VIII
EA201791803A1 (ru) 2015-02-10 2017-11-30 Джензим Корпорейшн Улучшенная доставка вирусных частиц в полосатое тело и кору больших полушарий
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
JP2018535929A (ja) * 2015-09-24 2018-12-06 バイオマリン ファーマシューティカル インコーポレイテッド アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤

Similar Documents

Publication Publication Date Title
RU2018114888A (ru) Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции
US20230047111A1 (en) Pharmaceutical formulations of tnf-alpha antibodies
JP2021523198A5 (enExample)
Nosaka et al. Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice
JP2015519382A5 (enExample)
EA027325B1 (ru) Составы этанерцепта, стабилизированные ксилитом
JP2023029500A (ja) 抗ヒトtslp受容体抗体含有医薬組成物
JP2019515899A5 (enExample)
JP2020537637A5 (enExample)
TWI745114B (zh) 用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品
Rodriguez et al. Umbilical cord: an allogenic tissue for potential treatment of COVID-19
CN1802171A (zh) 不包含血清白蛋白的人红细胞生成素的稳定水溶液
JP2017533252A (ja) C型肝炎のための長時間作用型医薬組成物
CN101199845B (zh) 一种稳定的抗IgE人源化单抗制剂
CN102327612A (zh) 一种稳定的人源化单克隆抗体制剂
NZ740521B2 (en) Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
RU2023105585A (ru) Стабильная экспрессия векторов на основе аденоассоциированного вируса у несовершеннолетних пациентов
RU2020140634A (ru) Стабильная экспрессия векторов на основе аденоассоциированного вируса у несовершеннолетних пациентов
JP2022518354A5 (enExample)
Schulz et al. Adverse Effects of Remdesivir for the Treatment of Acute COVID-19 in the Pediatric Population
OA17126A (en) Pharmaceutical formulations of TNF-alpha antibodies
Jennings et al. Effect of actinomycin D on the production of acute phase protein in the rabbit
NZ780570B2 (en) Adeno-associated virus Factor VIII vectors, associated viral particles and therapeutic formulations comprising the same